Combined Inhibition of Tumor Necrosis Factor α and Interleukin-17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody-Reference-Cited by-同舟云学术

Combined Inhibition of Tumor Necrosis Factor α and Interleukin-17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody

Published:2014-12-27 Issue:1 Volume:67 Page:51-62
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Fischer Jens A. A.¹,Hueber Axel J.²,Wilson Stacy³,Galm Margarete¹,Baum Wolfgang²,Kitson Christopher³,Auer Johannes¹,Lorenz Stefan H.¹,Moelleken Jörg¹,Bader Martin¹,Tissot Alain C.¹,Tan Seng-Lai³,Seeber Stefan¹,Schett Georg²

Affiliation:

1. Roche Pharmaceutical Research and Early Development; Penzberg Germany

2. University of Erlangen-Nuremberg; Erlangen Germany

3. Roche Pharmaceutical Research and Early Development; New York New York

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Reference46 articles.

1. The pathogenesis of rheumatoid arthritis;McInnes;N Engl J Med,2011

2. The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis;Firestein;J Clin Invest,2004

3. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis;Firestein;J Clin Rheumatol,2005